BMO Capital Downgrades Ra Pharma (RARX) to Market Perform on Pending Takeover
Tweet Send to a Friend
BMO Capital analyst Matthew Luchini downgraded Ra Pharma (NASDAQ: RARX) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
